HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
Last trade$102.36
Day change-$2.22 (-2.12%)
Day range$99.82 – $106.50
Volume212,714
Market cap$8.65B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$8.65B
Price / earnings
36.58×
Price / book
4.35×
Price / sales
6.35×
EV / sales
6.85×
EV / EBITDA
18.16×
Profitability
Earnings per share
$2.86
Return on assets
7.23%
Return on equity
11.88%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.47×
Current ratio
2.99×
Quick ratio
2.99×
Cash ratio
1.66×
Cash flow
Price / cash flow
17.65×
Price / free cash flow
18.5×
Free cash flow
$467.67M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HQY, quarterly periods
Line item
Q2 FY2027 Jul 31, 2026
Q1 FY2027 Apr 30, 2026
Q4 FY2026 Jan 31, 2026
Q3 FY2026 Oct 31, 2025
Q2 FY2026 Jul 31, 2025
Q1 FY2026 Apr 30, 2025
Q4 FY2025 Jan 31, 2025
Q3 FY2025 Oct 31, 2024
Revenue
$350.73M
$354.64M
$334.59M
$322.16M
$325.84M
$330.84M
$311.82M
$300.43M
Cost of revenue
$92.78M
$98.33M
$106.44M
$94.1M
$93.24M
$106.53M
$122.77M
$103.41M
Gross profit
$257.95M
$256.31M
$228.15M
$228.06M
$232.6M
$224.31M
$189.04M
$197.03M
Selling, general and administrative
$58.08M
$57.96M
$58.45M
$55.29M
$49.91M
$51.52M
$53.06M
$54.43M
Research and development
$73.92M
$67.77M
$70.35M
$65.92M
$64.8M
$61.44M
$64.65M
$60.19M
Total operating expenses
$159.26M
$153.36M
$157.08M
$149.37M
$142.98M
$141.23M
$146.89M
$177.4M
Operating income
$98.69M
$102.95M
$71.07M
$78.7M
$89.61M
$83.08M
$42.15M
$19.63M
Interest expense
-$12.61M
-$12.59M
-$13.27M
-$14.05M
-$14.96M
-$14.86M
-$15.26M
-$18.16M
Income before taxes
$87.87M
$92.41M
$60.9M
$67.53M
$78.05M
$70.95M
$29.96M
$6.22M
Income taxes
$22.22M
$23M
$11.16M
$15.84M
$18.19M
$17.04M
$3.6M
$515K
Net income
$65.64M
$69.42M
$49.74M
$51.69M
$59.85M
$53.92M
$26.37M
$5.7M
Net income attributable to common shareholders
$65.64M
$69.42M
$49.74M
$51.69M
$59.85M
$53.92M
$26.37M
$5.7M
EBITDA
$141.62M
$142.28M
$111.08M
$118.63M
$129.33M
$123.09M
$83.51M
$94.78M
Basic earnings per share
$0.79
$0.82
$0.58
$0.60
$0.69
$0.62
$0.30
$0.07
Diluted earnings per share
$0.78
$0.82
$0.57
$0.59
$0.68
$0.61
$0.29
$0.06
Recent news
Company coverage with links to the original publishers.
Aytu BioPharma reported a quarterly loss of $0.2 per share, missing consensus estimates of $0.1 loss, representing a -100% earnings surprise. The company posted revenues of $14.84 million, slightly beating estimates. With unfavorable estimate revisions, the stock received a Zacks Rank #5 (Strong Sell) rating and has declined 31.5% year-to-date versus the S&P 500's 10.5% gain.
Prime Medicine (PRME) reported a quarterly loss of $0.22 per share, beating consensus estimates of $0.23 loss by 4.35%, but missed revenue expectations with $4.21 million versus the consensus estimate, down 25.8%. The stock has outperformed the S&P 500 by 12.6% year-to-date but carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
CryoPort (CYRX) reported a quarterly loss of $0.25 per share, missing the consensus estimate of $0.19 loss by 31.58%. However, the company exceeded revenue expectations with $50.22 million versus the estimate of $48.68 million. The stock has gained 74% year-to-date but received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
A comparison of two Medical Services stocks shows that Bausch + Lomb (BLCO) is more attractive for value investors than HealthEquity (HQY). BLCO has a stronger Zacks Rank of #1 (Strong Buy) versus HQY's #2 (Buy), and superior valuation metrics including a lower forward P/E ratio (21.20 vs 21.96), a significantly better PEG ratio (0.53 vs 1.36), and a lower P/B ratio (1.1 vs 4.31), earning it a Value grade of B compared to HQY's C grade.
HealthEquity (HQY) is highlighted as a compelling growth stock investment opportunity, featuring a Growth Score of B and Zacks Rank #2. The company demonstrates strong fundamentals including 18% projected EPS growth (above the 14% industry average), robust year-over-year cash flow growth of 22%, and positive earnings estimate revisions, positioning it as a potential outperformer for growth investors.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.